Markets
OPK

Here's Why OPKO Health Stock Fell on Thursday

What happened

Shares of OPKO Health (NASDAQ: OPK), a diagnostics and biopharmaceutical company, fell hard today after the company announced a secondary share offering. Investors unhappy about dilution of the value of their shares pushed the stock 14.2% lower on Thursday.

So what 

After losing $141 million in the first half of 2019, the company finished June with $111 million in cash on its balance sheet and $68 million of high-interest debt that's due in 2020. That leaves it without a lot of options at the moment. Today the company announced a plan to raise $100 million by creating heaps of new shares that will dilute the shares investors have been holding.

Man drawing a downward sloping chart.

Image source: Getty Images.

OPKO hasn't announced pricing for its upcoming offering, but the dilution will be significant. The stock has fallen to just $1.63 per share. If it gets lucky and sells 50 million shares at $2 each, the outstanding share count will swell by around 14%.

Now what

OPKO announced its impending share offering shortly after announcing success in a non-inferiority test with somatrogon, a once-weekly growth hormone injection for children who don't produce enough on their own. The current standard, Genotropin from Pfizer (NYSE: PFE), is just as effective, but parents need to inject their children every day.

OPKO developed somatrogon in partnership with Pfizer and will receive a tiered royalty percentage that tops out in the mid-20s if it's approved. Somatrogon approval could push this biotech stock much higher in the short term, but anyone hoping the royalties will allow the company to finally stop losing money should prepare for disappointment. In the first half of 2019, Genotropin sales sank 15% to just $232 million.

10 stocks we like better than Opko Health
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Opko Health wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of June 1, 2019

 

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

OPK PFE

Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More